These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 11758578)
21. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
22. Teva v. Eisai: what's the real "controversy"? Wang GL Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831 [TBL] [Abstract][Full Text] [Related]
23. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Lietzan EK Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013 [TBL] [Abstract][Full Text] [Related]
24. Biosimilars: impact of differences with Hatch-Waxman. Kowalchyk K; Crowley-Weber C Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968 [TBL] [Abstract][Full Text] [Related]
25. Amendments to the Canadian Patent Act to address drug access: is help on the way? Penner MD; Narayanan P Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751 [No Abstract] [Full Text] [Related]
27. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
28. GATT implementation and generic drug approval. Safir PO; Lassman SM Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203 [No Abstract] [Full Text] [Related]
29. Judicial developments in the US Hatch-Waxman infringement safe harbor. Swirnoff AH; Becker DM Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449 [TBL] [Abstract][Full Text] [Related]
30. Delayed access to generic medicine: a comment on the Hatch-Waxman Act and the "approval bottleneck". Patel AN Fordham Law Rev; 2009 Nov; 78(2):1075-115. PubMed ID: 19938382 [TBL] [Abstract][Full Text] [Related]
31. The right to a jury trial in actions under the Waxman-Hatch Act. Coggio BD; Bresnick SA Food Drug Law J; 1997; 52(3):259-76. PubMed ID: 10343025 [No Abstract] [Full Text] [Related]
32. Supreme Court rules against drug patent "evergreening". Kondro W CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081 [No Abstract] [Full Text] [Related]
33. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009. Dougherty MP Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541 [TBL] [Abstract][Full Text] [Related]
34. FDA's role in making exclusivity determinations. Dickinson EH Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573 [No Abstract] [Full Text] [Related]
35. Patent infringement. Generic HIV drugmaker's patent claim is time-barred. AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916 [No Abstract] [Full Text] [Related]
36. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade. Grabowski H; Vernon J Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428 [TBL] [Abstract][Full Text] [Related]
37. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Son KB; Lopert R; Gleeson D; Lee TJ Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313 [TBL] [Abstract][Full Text] [Related]
38. The right to a jury trial under the Waxman-Hatch Act--the question revisited and resolved. Coggio BD; DeMasi TE Food Drug Law J; 2002; 57(1):155-60. PubMed ID: 12118478 [No Abstract] [Full Text] [Related]
39. US policy may encourage counterfeit drugs. Bouchie A Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826 [No Abstract] [Full Text] [Related]
40. How Patent Troll Legislation Can Increase Timely Access to Generic Drugs. Treasure CL; Kesselheim AS JAMA Intern Med; 2016 Jun; 176(6):729-30. PubMed ID: 27183456 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]